Lynparza for maintenance of breast cancer wiht PALB mutations – pro
while olaparib has some evidence for being effective in PALB mutations in the metastatic setting, I was not able to find any literature for its use for that mutaiton as maintenance. The aoppoeal refernced a study by Nadine M. Tung et al, but it was only a phase II study with a few patients who had PALB . Confirmed responses were seen only with gPALB2 (ORR, 82%) and sBRCA1/2 (ORR, 50%) mutations. This is insufficient evidence to establish SOC
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D’Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 Dec 20;38(36):4274-4282.
Lynparza, Prescribing Information 2023